Augmented blood sugar and insulin accompanying with NAFLD stimulate DNL and slow down the fatty acid oxidation, by distressing sterol regulatory element binding proteins (SREBP-1c) and carbohydrate responsive element binding proteins (ChREBP). Here, MLXIPL is linked to metabolic dysfunction-associated steatotic liver disease.